Health

FDA Grants Accelerated Approval to BMS for First-in-Class CELMoD Multiple Myeloma Therapy Zenbexus

The FDA has granted accelerated approval to Bristol Myers Squibb's Zenbexus (iberdomide), the first-in-class CELMoD therapy for relapsed or refractory…